Responses
E-Poster viewings
Ovarian Cancer
IGCS19-0608
270 Large single-site institution experience of testing for somatic and germline concordance BRCA1/2 pathogenic mutations in ovarian cancer patients eligible for PARP inhibitors therapy
Compose a Response to This Article
Other responses
No responses have been published for this article.